• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma

by MM360 Staff | Nov 7, 2025 | Uncategorized

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering multiple myeloma, based on results from the randomized phase 3 AQUILA trial.Daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen), a...

by MM360 Staff | Nov 7, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Oct 30, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Oct 30, 2025 | Uncategorized

Source: CURE articles Post Content Read More

by MM360 Staff | Oct 25, 2025 | Uncategorized

Source: CURE articles Post Content Read More

FDA OK’s belantamab mafodotin-blmf for multiple myeloma

by Matthew Shinkle | Oct 24, 2025 | Uncategorized

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain adults with relapsed or refractory multiple myeloma.This indication of belantamab mafodotin-blmf (Blenrep, GSK) applies to adults who have received...
« Older Entries
Next Entries »

Recent Content

  • Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma
  • The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience
  • (no title)
  • New center promotes advocacy for gynecological cancer patients
  • FDA clears Thermo Fisher EXTENT system for myeloma diagnosis
  • Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma
  • TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial
  • (no title)
  • (no title)
  • New ‘powerful’ lab test will help researchers explore blood cancer
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT